ZYBT vs ATXG vs CLPS

For growth investors, CLPS Incorporation (CLPS) is the stronger pick with 15.

2% revenue growth year-over-year, versus -18. 9% for Addentax Group Corp. (ATXG). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CLPS Incorporation (CLPS) delivered a total return of -69.

2%, compared to -99. 6% for Addentax Group Corp. (ATXG). Over 10 years, the gap is even starker: CLPS returned -78. 6% versus ATXG's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CLPS Incorporation (CLPS) is the lower-risk stock at 0.

19β versus Zhengye Biotechnology Holding Limited's 1. 75β — meaning ZYBT is approximately 796% more volatile than CLPS relative to the S&P 500. On balance sheet safety, Zhengye Biotechnology Holding Limited (ZYBT) carries a lower debt/equity ratio of 25% versus 103% for Addentax Group Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CLPS Incorporation (CLPS) is pulling ahead at 15.

2% versus -18. 9% for Addentax Group Corp. (ATXG). On earnings-per-share growth, the picture is similar: Addentax Group Corp. grew EPS -19. 7% year-over-year, compared to -181. 4% for CLPS Incorporation. Over a 3-year CAGR, CLPS leads at 2. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zhengye Biotechnology Holding Limited (ZYBT) is the more profitable company, earning 6.

1% net margin versus -121. 8% for Addentax Group Corp. — meaning it keeps 6. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYBT leads at 8. 8% versus -43. 5% for ATXG. At the gross margin level — before operating expenses — ZYBT leads at 49. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CLPS (14.

7% yield), ZYBT (5. 3% yield) pay a dividend. ATXG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CLPS Incorporation (CLPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 14. 7% yield). Both have compounded well over 10 years (CLPS: -78. 6%, ATXG: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYBT (Healthcare) and ATXG (Industrials) and CLPS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYBT is a small-cap income-oriented stock; ATXG is a small-cap quality compounder stock; CLPS is a small-cap high-growth stock. ZYBT, CLPS pay a dividend while ATXG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.